Amoxicillin/Clavulanate

Overview

Amoxicillin/clavulanate is a potentiated aminopenicillin antibiotic that combines the bactericidal activity of amoxicillin with the beta-lactamase–inhibiting effects of clavulanic acid. This combination expands the antimicrobial spectrum of amoxicillin by restoring activity against many bacteria that produce beta-lactamase enzymes.

In dogs and cats, amoxicillin/clavulanate is widely used for the treatment of common bacterial infections involving the skin, soft tissues, urinary tract, oral cavity, and respiratory tract when susceptible organisms are involved. The drug is particularly valuable for infections caused by mixed aerobic and anaerobic bacteria.

Mechanism of Action (MOA): Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death in actively dividing bacteria. Clavulanic acid has minimal antibacterial activity on its own but irreversibly binds to many beta-lactamases, preventing enzymatic inactivation of amoxicillin and allowing the antibiotic to retain its effectiveness.

Amoxicillin/clavulanate is a time-dependent antimicrobial, meaning clinical efficacy depends on maintaining drug concentrations above the minimum inhibitory concentration (MIC) for an adequate duration. For this reason, appropriate dosing intervals and treatment duration are essential for successful outcomes.

Indications

Amoxicillin/clavulanate is indicated in dogs and cats for the treatment of bacterial infections caused by susceptible organisms, particularly those producing beta-lactamase enzymes. It is most commonly used when broader coverage than amoxicillin alone is required.

• Skin and soft tissue infections: Including wounds, abscesses, cellulitis, and superficial to deep pyoderma caused by susceptible gram-positive bacteria, anaerobes, and mixed infections.
• Urinary tract infections (UTIs): Used for bacterial cystitis caused by susceptible organisms, although amoxicillin alone is often preferred for empirical treatment when beta-lactamase production is not suspected.
• Oral and periodontal infections (dogs): Effective against aerobic and anaerobic bacteria associated with canine periodontal disease.
• Respiratory tract infections: Used for upper respiratory tract infections when a bacterial component is suspected; ineffective against Mycoplasma spp, and resistance among Bordetella spp may limit efficacy in some regions.
• Mixed aerobic and anaerobic infections: Particularly useful when infections involve multiple bacterial populations, such as bite wounds and abscesses.

Dosage (Reference)

Amoxicillin/clavulanate dosing in dogs and cats is based on the combined total amount of both amoxicillin and clavulanic acid, unless otherwise specified. Because this is a time-dependent antimicrobial, consistent dosing intervals and appropriate treatment duration are essential.

Dog

Cat

Warnings & Precautions

Amoxicillin/clavulanate is generally well tolerated in dogs and cats, but appropriate patient selection and monitoring are important to minimize adverse effects and therapeutic failure.

• Hypersensitivity reactions: Contraindicated in animals with a known hypersensitivity to penicillins. Use cautiously in patients with documented allergy to other beta-lactam antibiotics (eg, cephalosporins, carbapenems) due to potential cross-reactivity.
• Severe systemic illness: Oral administration is not recommended in patients with septicemia, shock, or other life-threatening conditions, as gastrointestinal absorption may be delayed or unreliable. Parenteral therapy should be used in these cases.
• Renal disease: Use with caution in dogs and cats with chronic kidney disease. Azotemic cats have been shown to experience a higher frequency of adverse effects and altered drug disposition.
• Hepatic considerations: Although penicillins are not considered inherently hepatotoxic, elevated liver enzymes have been reported; use cautiously in patients with pre-existing hepatic disease.
• Antimicrobial stewardship: Should not be used empirically when narrower-spectrum agents (eg, amoxicillin alone) are appropriate, particularly for uncomplicated urinary tract infections.
• Resistance concerns: Ineffective against methicillin-resistant staphylococci and organisms producing beta-lactamases not inhibited by clavulanic acid; culture and susceptibility testing is recommended when possible.
• Duration of therapy: Prolonged or unnecessary use increases the risk of adverse effects and antimicrobial resistance; treatment duration should be guided by infection type and clinical response.
• Pregnancy and lactation: Crosses the placenta and is excreted in milk at low concentrations; use only when the expected benefits outweigh potential risks to offspring.

Drug Interactions

Clinically relevant drug interactions with amoxicillin/clavulanate in dogs and cats are primarily related to altered antimicrobial activity, changes in drug clearance, or increased risk of adverse effects. Most combinations are not absolutely contraindicated but require clinical judgment and monitoring.

• Aminoglycosides (eg, gentamicin, amikacin): Beta-lactam antibiotics can inactivate aminoglycosides in vitro and potentially in vivo, particularly in patients with chronic kidney disease; avoid mixing in the same syringe and monitor renal function.
• Bacteriostatic antimicrobials (eg, chloramphenicol, macrolides, tetracyclines, sulfonamides): In vitro antagonism with beta-lactam antibiotics has been reported; the clinical relevance is unclear, but concurrent use should be carefully justified.
• Methotrexate: Amoxicillin may reduce renal excretion of methotrexate, increasing the risk of methotrexate toxicity; concurrent use requires caution and monitoring.
• Mycophenolate: May decrease concentrations of mycophenolate’s active metabolite, potentially reducing immunosuppressive efficacy.
• Probenecid: Inhibits tubular secretion of penicillins, resulting in increased serum concentrations and prolonged half-life of amoxicillin.
• Warfarin: Concurrent use may increase the risk of bleeding due to altered anticoagulant effects; close monitoring is recommended.
• Leflunomide: Prior, concurrent, or subsequent use without an adequate washout period may increase the risk of hepatotoxicity.

Side Effects & Overdose

Side Effects

Adverse effects associated with amoxicillin/clavulanate in dogs and cats are generally uncommon and usually mild. When they occur, they are most often related to gastrointestinal disturbance or hypersensitivity reactions.

• Gastrointestinal effects: The most frequently reported adverse effects include decreased appetite, nausea, vomiting, and diarrhea, particularly with oral administration.
• Antibiotic-associated diarrhea: Alteration of normal gastrointestinal flora may result in diarrhea and, less commonly, superinfection with resistant organisms.
• Hypersensitivity reactions: Rare but potentially serious reactions may include fever, skin eruptions, pruritus, eosinophilia, neutropenia, thrombocytopenia, lymphadenopathy, or anaphylaxis.
• Neurologic effects: High doses or prolonged therapy may be associated with neurotoxicity such as ataxia, particularly in dogs.
• Hepatic effects: Although penicillins are not considered hepatotoxic, transient increases in liver enzyme activities have been reported.
• Renal disease considerations: Cats with azotemic chronic kidney disease may experience a higher frequency of adverse effects compared with non-azotemic cats.

Overdose

Acute overdose of amoxicillin/clavulanate in dogs and cats is unlikely to result in severe toxicity. Clinical signs are typically limited to gastrointestinal upset, although other adverse effects are possible with very high doses.

• Gastrointestinal distress: Vomiting, diarrhea, and anorexia are the most commonly observed signs following overdose.
• Neurologic signs: Extremely high doses, particularly in patients with renal impairment, may increase the risk of CNS effects.
• Management: Treatment is primarily supportive and symptomatic. Ensure adequate hydration and monitor for persistent gastrointestinal or neurologic signs.
• Poison consultation: For known or suspected significant overdose, consultation with a veterinary poison control center is recommended.

Key Notes

Practical clinical points to optimize the effective and responsible use of amoxicillin/clavulanate in dogs and cats:

• Expanded spectrum: Addition of clavulanic acid restores activity against many beta-lactamase–producing bacteria that are resistant to amoxicillin alone.
• Not effective against all pathogens: This combination is ineffective against methicillin-resistant staphylococci and organisms such as Mycoplasma spp; susceptibility testing should guide use.
• Time-dependent killing: Clinical efficacy depends on maintaining drug concentrations above the MIC; appropriate dosing intervals are critical.
• Urinary tract infections: Urine-specific breakpoints apply only to uncomplicated cystitis and should not be extrapolated to pyelonephritis or systemic infections.
• Empirical use considerations: For uncomplicated urinary infections, amoxicillin alone may be preferred initially due to high urinary concentrations and narrower spectrum.
• Product formulation awareness: Veterinary-labeled products express strength as the total of both components, whereas human-labeled products express strength as amoxicillin only; this difference is clinically important when calculating doses.
• Antimicrobial stewardship: Use the narrowest effective spectrum and shortest appropriate duration to minimize resistance development.
• Culture-guided therapy: Whenever possible, therapy should be adjusted based on culture and susceptibility results rather than prolonged empirical treatment.